Story
Biogen Stock Climbs on Analyst Upgrades Ahead of Key Alzheimer's Drug Catalysts
Summary
Shares of Biogen gained after several Wall Street analysts raised their price targets, citing optimism around upcoming clinical data for its Alzheimer's candidate diranersen and a potential FDA approval for a new Leqembi formulation.
Biogen (BIIB) shares rose 1.6% in pre-open trading as a flurry of Wall Street analyst upgrades bolstered investor confidence ahead of two significant pipeline catalysts for the company's Alzheimer's franchise. The stock traded at $202.17, up from its previous close of $198.91, amid a broadly positive market session.
Analyst Optimism Drives Gains
The rally was underpinned by several analyst price target increases, signaling renewed enthusiasm for the stock. The positive revisions included:
- Jefferies: Target raised to $255 from $210
- RBC Capital: Target raised to $242 from $227
- BofA Securities: Target raised to $217 from $203
These firms largely maintained their buy-equivalent ratings, pointing to two key upcoming events that could significantly impact Biogen's long-term outlook. The first is the presentation of detailed Phase 2 data for its Alzheimer's candidate diranersen at the AAIC conference in mid-July. The second is an anticipated FDA decision by August on a once-weekly subcutaneous starting dose for Leqembi, its partnered Alzheimer's treatment.
AdPipeline Catalysts and Market Impact
An approval for the subcutaneous Leqembi formulation would represent a meaningful commercial expansion, according to market observers. It would allow patients to begin treatment at home, a significant convenience factor beyond the currently approved weekly at-home maintenance dosing. This development could help accelerate the drug's uptake and revenue potential.
Broader market sentiment also provided a supportive backdrop. HSBC analysts noted in a report that biopharma M&A is trending toward a record year, citing Biogen's purchase of Apellis as a notable transaction. While Biogen faces near-term earnings pressure from elevated R&D and milestone charges—projected to cause a roughly 40% year-over-year EPS decline in the second quarter—investors appeared to focus on the longer-term growth drivers.